DALLAS--(BUSINESS WIRE)--Ikonisys, a leading provider of non-invasive, cell-based diagnostic solutions, announced today at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting that it has begun a clinical trial evaluating its breakthrough test for early detection of chromosomal abnormality trisomy 21. Early, non-invasive detection of genetic disorders, including Down syndrome, provides pregnant women with fast and accurate solutions that eliminate the need for repeat testing. Led by renowned physician Professor Kypros Nicolaides of King’s College Hospital in London, the trial aims to validate the use of circulating fetal cells in early prenatal detection of Down syndrome within the first trimester of pregnancy.
